Preventive treatments for breast cancer: recent developments

被引：6

作者：

Ales-Martinez, J. E. ^{[1
]}

Ruiz, A. ^{[2
]}

Chacon, J. I. ^{[3
]}

Lluch Hernandez, A. ^{[4
]}

Ramos, M. ^{[5
]}

Cordoba, O. ^{[6
]}

Aguirre, E. ^{[7
]}

Barnadas, A. ^{[8
]}

Jara, C. ^{[9
]}

Gonzalez, S. ^{[10
]}

Plazaola, A. ^{[11
]}

Florian, J. ^{[12
]}

Andres, R. ^{[13
]}

Sanchez Rovira, P. ^{[14
]}

Frau, A. ^{[15
]}

机构：

[1] Hosp Nuestra Senora de Sonsoles, GEICAM Spanish Breast Canc Grp, Avila, Spain

[2] GEICAM Spanish Breast Canc Grp, IVO, Valencia, Spain

[3] Hosp Virgen Salud, GEICAM Spanish Breast Canc Grp, Toledo, Spain

[4] Univ Valencia, Hosp Clin Univ Valencia INCLIVA, GEICAM Spanish Breast Canc Grp, Valencia, Spain

[5] GEICAM Spanish Breast Canc Grp, Ctr Oncol Galicia, La Coruna, Spain

[6] Hosp Univ Vall dHebron, GEICAM Spanish Breast Canc Grp, Barcelona, Spain

[7] Hosp Arnau Vilanova, GEICAM Spanish Breast Canc Grp, Lleida, Spain

[8] Hosp Santa Creu & Sant Pau, GEICAM Spanish Breast Canc Grp, Barcelona, Spain

[9] Hosp Univ Fdn Alcorcon, GEICAM Spanish Breast Canc Grp, Madrid, Spain

[10] Hosp San Pedro de Alcantara, GEICAM Spanish Breast Canc Grp, Caceres, Spain

[11] GEICAM Spanish Breast Canc Grp, Onkol, Guipuzcua, Spain

[12] Hosp Barbastro, GEICAM Spanish Breast Canc Grp, Huesca, Spain

[13] Hosp Clin Univ Lozano Blesa, GEICAM Spanish Breast Canc Grp, Zaragoza, Spain

[14] Complejo Hosp Jaen, GEICAM Spanish Breast Canc Grp, Jaen, Spain

[15] Hosp Prov Castellon, GEICAM Spanish Breast Canc Grp, Castellon de La Plana, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2015年 / 17卷 / 04期

关键词：

Breast cancer; Pharmacological prevention; GEICAM; Aromatase inhibitors; BRCA; Breast cancer prevention; SURGICAL ADJUVANT BREAST; BOWEL PROJECT; RISK; TAMOXIFEN; WOMEN; CHEMOPREVENTION; RALOXIFENE; MODEL; PREDICTION; EXEMESTANE;

D O I：

10.1007/s12094-014-1250-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer is a burden for western societies, and an increasing one in emerging economies, because of its high incidence and enormous psychological, social, sanitary and economic costs. However, breast cancer is a preventable disease in a significant proportion. Recent developments in the armamentarium of effective drugs for breast cancer prevention (namely exemestane and anastrozole), the new recommendation from the National Institute for Health and Care Excellence to use preventative drugs in women at high risk as well as updated Guidelines from the US Preventive Services Task Force and the American Society of Clinical Oncology should give renewed momentum to the pharmacological prevention of breast cancer. In this article we review recent major developments in the field and examine their ongoing repercussion for breast cancer prevention. As a practical example, the potential impact of preventive measures in Spain is evaluated and a course of practical actions is delineated.

引用

页码：257 / 263

页数：7

共 28 条

[21] Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers [J].

Phillips, Kelly-Anne ;

Milne, Roger L. ;

Rookus, Matti A. ;

Daly, Mary B. ;

Antoniou, Antonis C. ;

Peock, Susan ;

Frost, Debra ;

Easton, Douglas F. ;

Ellis, Steve ;

Friedlander, Michael L. ;

Buys, Saundra S. ;

Andrieu, Nadine ;

Nogues, Catherine ;

Stoppa-Lyonnet, Dominique ;

Bonadona, Valerie ;

Pujol, Pascal ;

McLachlan, Sue Anne ;

John, Esther M. ;

Hooning, Maartje J. ;

Seynaeve, Caroline ;

Tollenaar, Rob A. E. M. ;

Goldgar, David E. ;

Terry, Mary Beth ;

Caldes, Trinidad ;

Weideman, Prue C. ;

Andrulis, Irene L. ;

Singer, Christian F. ;

Birch, Kate ;

Simard, Jacques ;

Southey, Melissa C. ;

Olsson, Hakan L. ;

Jakubowska, Anna ;

Olah, Edith ;

Gerdes, Anne-Marie ;

Foretova, Lenka ;

Hopper, John L. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (25) :3091-3099

[22] Mammographic density and risk of breast cancer according to tumor characteristics and mode of detection: a Spanish population-based case-control study [J].

Pollan, Marina ;

Ascunce, Nieves ;

Ederra, Maria ;

Murillo, Alberto ;

Erdozain, Nieves ;

Enrique Ales-Martinez, Jose ;

Pastor-Barriuso, Roberto .

BREAST CANCER RESEARCH, 2013, 15 (01)

[23] Survival Outcomes After Contralateral Prophylactic Mastectomy: A Decision Analysis [J].

Portschy, Pamela R. ;

Kuntz, Karen M. ;

Tuttle, Todd M. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (08)

[24]

Raphael J, 2014, J CLIN ONCOL S26, V32

[25] A breast cancer prediction model incorporating familial and personal risk factors [J].

Tyrer, J ;

Duffy, SW ;

Cuzick, J .

STATISTICS IN MEDICINE, 2004, 23 (07) :1111-1130

[26] Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers [J].

Vicus, Danielle ;

Rosen, Barry ;

Lubinski, Jan ;

Domchek, Susan ;

Kauff, Noah D. ;

Lynch, Henry T. ;

Isaacs, Claudine ;

Tung, Nadine ;

Sun, Ping ;

Narod, Steven A. .

GYNECOLOGIC ONCOLOGY, 2009, 115 (01) :135-137

[27] Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer [J].

Vogel, Victor G. ;

Costantino, Joseph P. ;

Wickerham, D. Lawrence ;

Cronin, Walter M. ;

Cecchini, Reena S. ;

Atkins, James N. ;

Bevers, Therese B. ;

Fehrenbacher, Louis ;

Pajon, Eduardo R. ;

Wade, James L., III ;

Robidoux, Andre ;

Margolese, Richard G. ;

James, Joan ;

Runowicz, Carolyn D. ;

Ganz, Patricia A. ;

Reis, Steven E. ;

McCaskill-Stevens, Worta ;

Ford, Leslie G. ;

Jordan, V. Craig ;

Wolmark, Norman .

CANCER PREVENTION RESEARCH, 2010, 3 (06) :696-706

[28] Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes - The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial [J].